QTTB: SEC Form SCHEDULE 13G filed by Q32 Bio Inc.
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for QTTB
Across the 21 sessions after earlier QTTB headlines, the stock closed higher 10 times and lower 11 times, with a median move of 7.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | QTTB | SPY |
|---|---|---|---|
| Oct 12, 2026 | Leerink Partners initiated coverage on Q32 Bio with a new price target | +4.8% | -0.1% |
| Sep 30, 2026 | Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026 | -13.2% | -0.2% |
| Sep 28, 2026 | Jefferies initiated coverage on Q32 Bio with a new price target | +5.2% | -0.7% |
| Sep 21, 2026 | Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026 | -0.7% | +1.6% |
| Sep 14, 2026 | Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer | -1.7% | -0.4% |
| Sep 1, 2026 | Q32 Bio to Participate in Upcoming September Investor Conferences | -3.4% | -0.7% |
Quantisnow market dataNASDAQ
QTTB
Q32 Bio Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2018
Get push alerts for QTTB
Full QTTB profile on Quantisnow Follow QTTB and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time